FILING ANALYSIS · THURSDAY, NOVEMBER 12
Theriva Biologics, Inc. TOVX — 8-K: Results of Operations and Financial Condition
neutral
Theriva Biologics reported a sale of SYN-004 for $350,000 upfront and up to $91 million in aggregate milestones, and announced VIRAGE2 enrollment is expected to complete in Q4 2026, but cash runway is only into Q1 2027, raising concerns about future funding needs.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →